Although the conventional view is that breast cancer is a lesser immunogenic cancer type, the inhibitor anti-PD-1/PD-L1 inhibitor has become the predominant in breast cancer immunotherapy (5, 6). This evidence concerns the gene CD274 and breast cancer.